Table 1.
Baseline characteristics of both groups (median/interquartile range)
| Parameter | HIP | IV sucrose | p-value |
|---|---|---|---|
| Number of patients (Randomized) |
18 |
22 |
|
| Age(years) |
76 (66–83) |
66 (58–76) |
0.10 |
| Sex |
Male −13 Female −5 |
Male −12 Female −10 |
0.33 |
| Race |
Caucasians −16 Africans −1 Others −1 |
Caucasians- 15 Africans-6 Others-1 |
0.12 |
| Blood pressure (mm Hg) Systolic |
130 (122–140) |
131 (124–140) |
0.85 |
| Blood pressure (mm Hg) Diastolic |
67 (62–75) |
68 (60–72) |
0.76 |
| Hemoglobin(g/L) |
110.5 (104–119) |
108.5 (102–117) |
0.39 |
| Serum ferritin(ug/L) |
71 (40–143) |
67 (27–100) |
0.59 |
| TSAT |
17 (14–20) |
16.5 (10–20) |
0.37 |
| Patients on ESA* |
7 |
6 |
1.0 |
| Average ESA dose (ug/month) |
60(60–80) |
80(60–100) |
0.20 |
| Serum creatinine(umol/L) |
246.5 (206–362) |
216.5 (176–351) |
0.48 |
| Glomerular filtration rate(ml/min/1.73 m2) |
20.5 (12–26) |
23 (18–33) |
0.39 |
| Serum albumin |
38 (35–39) |
38.5 (36–41) |
0.58 |
| Intact PTH |
13.05 (6.1-20.1) |
13.3 (7.9-16.75) |
0.93 |
| Serum phosphate |
1.28 (1.07-1.42) |
1.28 (1–1.54) |
0.96 |
| Cause Of ESRD | Diabetes – 6 Ischemic nephropathy-3 Hypertension – 3 Unknown – 3 Others – 3 | Diabetes −9 Ischemic nephropathy-6 Hypertension – 1 Unknown – 5 Others – 1 | 0.22 |